Skip to main content

Advertisement

Table 2 Response according to mutational status

From: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

  KRAS exon 2
wt vs. mt
RAS
wt vs. mt
PIK3CA/BRAF
wt vs. mt
RAS/PIK3CA/BRAF
All wt vs. any mt
Responder (n) 23 vs. 17 21 vs. 19 38 vs. 2 18 vs. 22
Non-responder (n) 19 vs. 18 15 vs. 21 31 vs. 5 10 vs. 26
ORR (%) 54.8 vs. 48.6 58.4 vs. 47.5 55.1 vs. 28.6 64.3 vs. 45.9
Difference in ORR 6.8 10.9 26.5 18.4
P value* 0.651 0.368 0.246 0.155
  1. Responder, CR + PR; Non-responder, SD + PD + NE; ORR, overall response rate; wt, wild-type; mt, mutant
  2. *calculated using Fisher’s exact test